CALR and congenital heart block: Commencing hydroxychloroquine ideally preconception or in early pregnancy may reduce the risk of congenital heart block in fetuses exposed to maternal anti-Ro/La autoantibodies, especially in women who had a previous infant diagnosed with congenital heart block [17], reducing recurrence from 21 to 7.5%.